COSTEM 2021 | The potential of CAR-T in CLL
Robin Foà
• 13 Oct 2021
Robin Foà, MD, Sapienza University of Rome, Rome, Italy, talks on the potential use of chimeric antigen receptor T-cell therapy (CAR-T) to treat patients with chronic lymphocytic leukemia (CLL). Prof. Foà describes how patients with unfavourable genetic profiles are generally offered allogeneic hematopoietic stem cell transplantation (allo-HSCT) and that CAR-T therapy may be an alternative option for a subset of patients with poor prognostic genetic markers including 17p deletion and p53 mutation who relapse after first-line treatment. This interview took place at the 6th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM), which took place virtually.
